

Haematologica
HAEMATOL/2019/224360
Version 4

Excluding myeloma diagnosis using revised thresholds for serum free
light chain ratios and M-protein levels

Jennifer L. J. Heaney, Alex Richter, Stella Bowcock, Guy Pratt, J.
Anthony Child, Graham Jackson, Gareth Morgan, Ingemar Turesson,
and Mark T. Drayson

Disclosures: Disclosures: MTD reports personal fees and other from Abingdon Health, outside the submitted work. GP reports personal fees from Binding Site Ltd, Amgen, Janssen, Celgene, Takeda and Gilead, outside of the submitted work. GJ reports personal fees and funding from Amgen, Takeda, J and J, Celgene, Roche and Onyx, outside the submitted work. GM reports personal fees from Amgen, Celgene, Janssen, and Takeda, outside the submitted work. All other authors declare no competing interests.

Contributions: JH, SB, GP and MTD wrote the manuscript. MTD designed the investigation into alternative reference ranges to increase specificity without loss of sensitivity in myeloma. JH and MTD analysed and interpreted the data. JAC, GJM, MTD, GHJ designed the Myeloma IX and Myeloma XI trials. IT and MTD designed the Swedish MGUS study. All authors commented on or approved the manuscript